The FDA told MannKind Corp. in a complete response letter that before the agency could approve the firm's inhaled diabetes drug Afrezza (insulin human rDNA origin), regulators needed more information about its clinical utility and comparison data about the newer version of the drug's inhaler device vs. the one tested in pivotal clinical trials. (BioWorld Today) Read More
